JAMA:行为干预减少医生不合理的抗生素处方

2016-02-10 MedSci MedSci原创

 临床上抗生素的过度使用导致病人暴露在不必要的不良反应的风险中,增加了医疗支出并且增加了抗生素耐药菌的流行。基于行为科学的干预或许可以减少不合理的抗生素处方。为了评价门诊治疗急性呼吸道感染行为干预的作用和不合理的抗生素处方。 为此,研究人员开展了一项集落随机临床试验。这项试验在波士顿和洛杉矶的47个基层保健实践中进行。参与者是248名临床医生,他们随机分组在18个月内分别接受了

临床上抗生素的过度使用导致病人暴露在不必要的不良反应的风险中,增加了医疗支出并且增加了抗生素耐药菌的流行。基于行为科学的干预或许可以减少不合理的抗生素处方。为了评价门诊治疗急性呼吸道感染行为干预的作用和不合理的抗生素处方。


为此,研究人员开展了一项整群随机临床试验。这项试验在波士顿和洛杉矶的47个基层保健实践中进行。参与者是248名临床医生,他们随机分组在18个月内分别接受了0、1、2或者3种干预。所有的临床医生在召集期间接受了抗生素处方指南的教育。干预始于2011年11月1日,直到2012年10月1日结束。有并发症和其他感染的患者被排除在外。三种行为干预或是单独实施,或者联用。这包括了建议选择(suggested alternatives)、可解释的理由(accountable justification)和同行对比(peer comparison)。第一种干预是给医生电子表单可以开具其他非抗生素的治疗药物;第二种干预是促使医生将处方记录进入病人的电子医疗档案中;第三种是发送邮件给临床医生,与其他最低的不合理处方率的医生进行对比。此次研究共有14375名病人参与(平均年龄47岁,69%是女性)。

此项研究表明,合适的行为干预,如可解释的理由和同行对比可以减少急性呼吸道感染的抗生素不合理处方率。

原始出处:
Meeker D, Linder JA, Fox CR, et al. Effect of Behavioral Interventions on Inappropriate Antibiotic Prescribing Among Primary Care Practices: A Randomized Clinical Trial.JAMA. 2016;315(6):562-570. doi:10.1001/jama.2016.0275.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1949265, encodeId=a524194926571, content=<a href='/topic/show?id=9a4f554245d' target=_blank style='color:#2F92EE;'>#抗生素处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55424, encryptionId=9a4f554245d, topicName=抗生素处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Aug 07 06:56:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63899, encodeId=74866389975, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Thu Feb 11 09:29:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63900, encodeId=c4cd63900c5, content=控制抗生素滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Thu Feb 11 09:29:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63861, encodeId=82af6386193, content=具体措施, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Feb 11 07:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63850, encodeId=5ea0638505c, content=希望早期实行, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Wed Feb 10 21:09:00 CST 2016, time=2016-02-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1949265, encodeId=a524194926571, content=<a href='/topic/show?id=9a4f554245d' target=_blank style='color:#2F92EE;'>#抗生素处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55424, encryptionId=9a4f554245d, topicName=抗生素处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Aug 07 06:56:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63899, encodeId=74866389975, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Thu Feb 11 09:29:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63900, encodeId=c4cd63900c5, content=控制抗生素滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Thu Feb 11 09:29:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63861, encodeId=82af6386193, content=具体措施, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Feb 11 07:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63850, encodeId=5ea0638505c, content=希望早期实行, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Wed Feb 10 21:09:00 CST 2016, time=2016-02-10, status=1, ipAttribution=)]
    2016-02-11 lietome1

    学习!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1949265, encodeId=a524194926571, content=<a href='/topic/show?id=9a4f554245d' target=_blank style='color:#2F92EE;'>#抗生素处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55424, encryptionId=9a4f554245d, topicName=抗生素处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Aug 07 06:56:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63899, encodeId=74866389975, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Thu Feb 11 09:29:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63900, encodeId=c4cd63900c5, content=控制抗生素滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Thu Feb 11 09:29:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63861, encodeId=82af6386193, content=具体措施, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Feb 11 07:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63850, encodeId=5ea0638505c, content=希望早期实行, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Wed Feb 10 21:09:00 CST 2016, time=2016-02-10, status=1, ipAttribution=)]
    2016-02-11 lietome1

    控制抗生素滥用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1949265, encodeId=a524194926571, content=<a href='/topic/show?id=9a4f554245d' target=_blank style='color:#2F92EE;'>#抗生素处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55424, encryptionId=9a4f554245d, topicName=抗生素处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Aug 07 06:56:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63899, encodeId=74866389975, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Thu Feb 11 09:29:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63900, encodeId=c4cd63900c5, content=控制抗生素滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Thu Feb 11 09:29:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63861, encodeId=82af6386193, content=具体措施, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Feb 11 07:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63850, encodeId=5ea0638505c, content=希望早期实行, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Wed Feb 10 21:09:00 CST 2016, time=2016-02-10, status=1, ipAttribution=)]
    2016-02-11 医者仁心5538

    具体措施

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1949265, encodeId=a524194926571, content=<a href='/topic/show?id=9a4f554245d' target=_blank style='color:#2F92EE;'>#抗生素处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55424, encryptionId=9a4f554245d, topicName=抗生素处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Aug 07 06:56:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63899, encodeId=74866389975, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Thu Feb 11 09:29:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63900, encodeId=c4cd63900c5, content=控制抗生素滥用, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=841a1636000, createdName=lietome1, createdTime=Thu Feb 11 09:29:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63861, encodeId=82af6386193, content=具体措施, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Feb 11 07:39:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63850, encodeId=5ea0638505c, content=希望早期实行, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Wed Feb 10 21:09:00 CST 2016, time=2016-02-10, status=1, ipAttribution=)]
    2016-02-10 1de3b290m83(暂无匿称)

    希望早期实行

    0

相关资讯

BMJ:行为干预有助于减肥后体重维持

肥胖是全球引起发病率和死亡率的最主要原因之一,而减肥可导致发病率和死亡率风险降低。系统评价证据提示,通过改变进食和体力活动达到长期减肥是可行的。然而,非手术治疗对减肥后体重维持的长期疗效仍不清楚。 为此,来自美国纽卡素大学的Sniehotta教授及其团队进行了一项研究,对当前肥胖成年人减肥后体重维持的方法进行系统性回顾和描述,并评估这些干预措施的有效性。该研究结果在线发表在2014年05月14日

2012 HFSA年会:干预抑郁症可降低心衰死亡率

  西雅图——美国心力衰竭学会(HFSA)2012年会上公布的一项随机研究显示,注重预防和管理抑郁的认知生物行为干预可减少心力衰竭的不良结局。   在这项研究中,肯塔基大学护理学院院长Debra K. Moser教授及其同事纳入278例已接受稳定剂量药物治疗至少1个月、在过去3个月内未发生心肌梗死或卒中且无任何认知功能障碍的心力衰竭患者,分成3组:生物行为干预组(同时实施认知行为治疗和生物反馈放

Lancet Dia & Endo:单一行为干预对肥胖孕妇的影响不明显

行为干预可能对肥胖孕妇的临床治疗效果有所改善。研究人员意在调查通过干预饮食和行为活动是否可以降低孕妇患有妊娠糖尿病和大于胎龄儿的概率。    英国成年女子孕期良好膳食和活动试验(UPBEAT)是一项在含有多种族的英国市中心地区的九家医院实施过的一项随机对照试验。研究人员招募16岁以上的肥胖孕妇(15至18周零6天的妊娠期)(BMI≥30 kg/m2)。研究人员根据计算